Shian-Jiun Shih

Dr. Shih is CEO and co-founder of Cellentia, a bioassay service provider that empowers biopharma clients to accelerate novel drug development. She served as VP of Product Development at Tessa Therapeutics from 2016-2021, leading analytical and process development for cell therapy products, viral vectors, external GMP, and biomarkers. Previously, she directed 29 scientists in immunoassays, nucleic acid-based assays, next-gen sequencing, mass spectrometry, flow cytometry, cell-based assays, IHC, and bioinformatics at Merck for six years.
With an eight-year tenure at Cell Genesys, Dr. Shih managed quality control and clinical monitoring assays for phase 3 clinical trials and addressing regulatory inquiries by product characterization. She also developed liquid formulations and explored novel drug delivery routes at Bayer Pharmaceuticals. Her seven years at Aventis encompassed roles in purification, formulation, and medical device development.
Dr. Shih holds a BS in Chemistry from National Taiwan University, a Ph.D. in Biochemistry from the University of Wisconsin–Madison, and completed post-doctoral training in Molecular Pharmacology at Stanford University.